Literature DB >> 32559847

Association between the microbiota and women's cancers - Cause or consequences?

Negin Alizadehmohajer1, Samaneh Shojaeifar2, Reza Nedaeinia3, Mojgan Esparvarinha4, Forogh Mohammadi5, Gordon A Ferns6, Majid Ghayour-Mobarhan7, Mostafa Manian8, Adele Balouchi9.   

Abstract

Breast, ovarian and uterine cancers are the most common neoplasms among women. Several mechanisms may be involved in oncogenesis and these include environmental and genetic factors. Bacteria may affect the development of some cancers, with bacterial components, their products and metabolites interacting with susceptible tissues. Commensalism and dysbiosis are important potential mechanisms involved in oncogenesis, and an effective strategy for diagnosis and treatment is required. The purpose of this review was to analyze the complex associations between these cancers in women, and the microbiota, specifically bacterial microbes. However, several cancers have an increased prevalence among individuals with HIV and HPV so the relationship between viral infections and malignancies in women is also referred to. We described how different phylum of bacteria, particularly in the gut, mammary tissue and vaginal microbiome may be involved in carcinogenesis; and we discuss the potential pathways involved: (I), that lead to cell proliferation, (II), immune system perturbation, (III), cell metabolic changes (e.g., hormonal factors), and (IV), DNA damage. Studies investigating the differences between the composition of the bacterial microbiota of healthy women compared to that present in various conditions, and the clinical trials are summarized for the few studies that have addressed the microbiota and related conditions, are also reviewed.
Copyright © 2020 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Bacterial microbiota; DNA damage; Dysbiosis mechanisms; Women’s cancers

Mesh:

Year:  2020        PMID: 32559847     DOI: 10.1016/j.biopha.2020.110203

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  7 in total

1.  Microbiome composition indicate dysbiosis and lower richness in tumor breast tissues compared to healthy adjacent paired tissue, within the same women.

Authors:  Maria Valeria Esposito; Bruno Fosso; Marcella Nunziato; Graziano Pesole; Francesco Salvatore; Giorgio Casaburi; Valeria D'Argenio; Alessandra Calabrese; Massimiliano D'Aiuto; Gerardo Botti
Journal:  BMC Cancer       Date:  2022-01-03       Impact factor: 4.430

2.  Comparative Analysis of Vaginal Microbiota in Women with Breast Cancer in Kazakhstan.

Authors:  Farida K Balmaganbetova; Ainur Amanzholkyzy; Roza E Nurgaliyeva; Aiman T Kaldybayeva; Azhar N Zhexenova
Journal:  Asian Pac J Cancer Prev       Date:  2021-04-01

Review 3.  The Relationship Between Microbial Community and Breast Cancer.

Authors:  Xuelian Song; Changran Wei; Xiangqi Li
Journal:  Front Cell Infect Microbiol       Date:  2022-06-16       Impact factor: 6.073

Review 4.  Gut Metabolites and Breast Cancer: The Continuum of Dysbiosis, Breast Cancer Risk, and Potential Breast Cancer Therapy.

Authors:  Kayla Jaye; Dennis Chang; Chun Guang Li; Deep Jyoti Bhuyan
Journal:  Int J Mol Sci       Date:  2022-08-22       Impact factor: 6.208

5.  In-Silico Characterization of Estrogen Reactivating β-Glucuronidase Enzyme in GIT Associated Microbiota of Normal Human and Breast Cancer Patients.

Authors:  Fatima Muccee; Shakira Ghazanfar; Wajya Ajmal; Majid Al-Zahrani
Journal:  Genes (Basel)       Date:  2022-08-27       Impact factor: 4.141

6.  Increased diversity of a cervical microbiome associates with cervical cancer.

Authors:  Natalia Zeber-Lubecka; Maria Kulecka; Bogusław Lindner; Ryszard Krynicki; Agnieszka Paziewska; Andrzej Nowakowski; Mariusz Bidzinski; Jerzy Ostrowski
Journal:  Front Oncol       Date:  2022-09-28       Impact factor: 5.738

Review 7.  Components of the Lectin Pathway of Complement in Solid Tumour Cancers.

Authors:  Maciej Cedzyński; Anna S Świerzko
Journal:  Cancers (Basel)       Date:  2022-03-17       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.